{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:57:10Z","timestamp":1792180630100,"version":"4.4.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["01-10026\/0010396\/01\/221\/221\/0\/2026"],"award-info":[{"award-number":["01-10026\/0010396\/01\/221\/221\/0\/2026"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Ketamine and esketamine are increasingly used for treatment-resistant depressive disorders, particularly when rapid symptom reduction is clinically desirable. Intranasal esketamine has a product-specific regulatory framework in several jurisdictions, whereas most racemic ketamine formulations remain off-label for psychiatric indications. This narrative review provides practical recommendations for psychiatrists considering short-term ketamine interventions in depressive disorders, with emphasis on oral solution, oral tablets, subcutaneous injection, and nasal spray formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review and clinical-practice synthesis of PubMed\/MEDLINE-indexed literature, open bibliographic sources, and regulatory documents, searched through 20 July 2026. Search concepts covered ketamine and esketamine, treatment-resistant major depressive disorder, intravenous, oral, subcutaneous, and intranasal administration, dosing, monitoring, treatment setting, substance-use risk, misuse\/diversion, and short-term intervention. Evidence was prioritized by study design and regulatory status; practical recommendations were categorized according to whether they were label-supported, directly evidence-supported, or based mainly on expert-practice synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evidence is strongest for labeled intranasal esketamine and intravenous racemic ketamine. Among the non-IV approaches reviewed here, subcutaneous racemic ketamine has coherent randomized evidence for flexible-dose short-term treatment; oral ketamine has limited but supportive small-trial and systematic-review evidence, with newer prolonged-release tablets remaining formulation-specific and investigational; and compounded racemic intranasal ketamine has weaker, more heterogeneous evidence. For all off-label racemic formulations, optimal dosing, frequency, durability, long-term safety, misuse risk, and maintenance strategy remain incompletely established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term ketamine treatment should be protocolized, measurement-based, supervised, time-limited, and embedded in a broader treatment plan for depressive disorders. For off-label racemic ketamine, the best-supported non-IV short-term regimen is supervised subcutaneous dosing with response-guided titration. Oral ketamine may be considered when parenteral or regulated nasal options are inaccessible, but it requires cautious patient selection, controlled dispensing, and objective monitoring. Esketamine nasal spray should follow the approved product label where available, whereas compounded racemic nasal ketamine should be reserved for exceptional circumstances.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1931248","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:57:21Z","timestamp":1788443841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term ketamine interventions for depressive disorders: practical best-practice recommendations for psychiatrists using oral, subcutaneous, and nasal formulations"],"prefix":"10.3389","volume":"17","author":[{"given":"Anita","family":"S\u0142upska","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Swieczkowski","sequence":"additional","affiliation":[{"name":"Department of Exercise Physiology and Functional Anatomy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144","place":["Bydgoszcz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Szarmach","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"S\u0142upski","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"W\u0142odarczyk","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review","volume":"8","author":"Walsh","year":"2022","journal-title":"BJPsych Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2020.1836399","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance","volume":"22","author":"Kasper","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.62","article-title":"Guidelines for ketamine use in clinical psychiatry practice","volume":"10","author":"Jelen","year":"2024","journal-title":"BJPsych Open"},{"key":"B5","unstructured":"FDA Warns Patients and Health Care Providers About Potential Risks Associated With Compounded Ketamine Products, Including Oral Formulations, for the Treatment of Psychiatric Disorders\n          \n          2023"},{"key":"B6","unstructured":"Spravato (Esketamine) Nasal Spray, CIII: Full Prescribing Information\n          \n          2026"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1317","article-title":"Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial","volume":"82","author":"Janik","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19f12820","article-title":"Oral ketamine for depression, 1: pharmacologic considerations and clinical evidence","volume":"80","author":"Andrade","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br J Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2018.196","article-title":"Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"214","author":"Domany","year":"2019","journal-title":"Br J Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2023.2169349","article-title":"Oral ketamine for depression: an updated systematic review","volume":"24","author":"Meshkat","year":"2023","journal-title":"World J Biol Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18r12475","article-title":"Oral ketamine for depression: a systematic review","volume":"80","author":"Rosenblat","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03063-x","article-title":"Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial","volume":"30","author":"Glue","year":"2024","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.19121","article-title":"Oral prolonged-release ketamine for treatment-resistant depression: two randomized clinical trials","volume":"9","author":"Walter","year":"2026","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.648691","article-title":"Intranasal ketamine for depression in adults: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"12","author":"An","year":"2021","journal-title":"Front Psychol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122773","article-title":"The efficacy and safety of intranasal formulations of ketamine and esketamine for the treatment of major depressive disorder: a systematic review","volume":"15","author":"Boudieu","year":"2023","journal-title":"Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020173","article-title":"Safety and tolerability of the acute ketamine treatment in treatment-resistant depression: focus on comorbidities interplay with dissociation and psychomimetic symptoms","volume":"16","author":"W\u0142odarczyk","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.01.207","article-title":"Ketamine for major depressive disorder during an inpatient psychiatric admission: effectiveness, adverse events, and lessons learned","volume":"351","author":"Brody","year":"2024","journal-title":"J Affect Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jad.2025.04.017","article-title":"Combination of ketamine and electroconvulsive therapy in treatment resistant depression","volume":"381","author":"K\u00f6k Kendirlio\u011flu","year":"2025","journal-title":"J Affect Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00897-2","article-title":"Non-parenteral ketamine for depression: a practical discussion on addiction potential and recommendations for judicious prescribing","volume":"36","author":"Swainson","year":"2022","journal-title":"CNS Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"29","author":"Smith-Apeldoorn","year":"2024","journal-title":"Mol Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.513068","article-title":"Subcutaneous ketamine in depression: a systematic review","volume":"12","author":"Cavenaghi","year":"2021","journal-title":"Front Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.577","article-title":"Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depressive disorder for use by adult specialist mental health services in New Zealand","volume":"9","author":"Beaglehole","year":"2023","journal-title":"BJPsych Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1316108","article-title":"Psychiatric and legal considerations for ketamine treatment within prison settings","volume":"15","author":"Bayrhammer-Savel","year":"2024","journal-title":"Front Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1931248\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:57:22Z","timestamp":1788443842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1931248\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":29,"alternative-id":["10.3389\/fpsyt.2026.1931248"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1931248","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1931248"}}